The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
TSLC1 Gene Silencing in Cervical Cancer Cell Lines and Cervical Neoplasia
Open accessAbstract
BACKGROUND: Cervical carcinogenesis is initiated by infection with high-risk (i.e., carcinogenic) human papillomavirus (HPV) types. The subsequent progression from premalignant cervical intraepithelial neoplasia (CIN) to invasive cancer is driven by both genetic and epigenetic processes. We assessed the role of the gene encoding the adhesion molecule tumor suppressor in lung cancer 1 (TSLC1) in this progression. METHODS: We analyzed TSLC1 gene expression by real-time quantitative reverse transcription-polymerase chain reaction, promoter methylation by sodium bisulfite genomic DNA sequencing, and allelic loss by microsatellite analysis in primary keratinocytes, in four non-tumorigenic HPV-immortalized human keratinocyte cell lines, and in 11 human cervical cancer cell lines that were positive for a high-risk HPV DNA type and in normal cervical epithelial cells. We transfected cervical cancer SiHa cells that did not express TSLC1 mRNA with an expression vector containing the TSLC1 complementary DNA (cDNA) or an empty vector and analyzed transfectants for anchorage-independent growth and tumorigenicity in nude mice. We also examined TSLC1 promoter methylation in premalignant cervical lesions and in cervical carcinomas and smears. All statistical tests were two-sided. RESULTS: TSLC1 mRNA was strongly reduced, relative to levels in primary keratinocytes, or absent in 10 (91%) of 11 cervical carcinoma cell lines but in none (0%) of the four HPV-immortalized cell lines (difference = 91%, 95% confidence interval [CI] = 74% to 100%; P =.004). The TSLC1 promoter was hypermethylated, relative to normal foreskin and cervical epithelial cells, in nine (82%) of the 11 cervical carcinoma cell lines but in none (0%) of the four HPV-immortalized cell lines (difference = 82%, 95 CI = 59% to 100%; P =.01). Seven (88%, 95% CI = 47% to 100%) of the eight SiHa/TSLC1 transfectants displayed a marked reduction in anchorage-independent growth (i.e., 0-100 colonies per 5000 cells) compared with none of the four (0%, 95% CI = 0% to 60%) SiHa transfectants bearing the empty vector (i.e., SiHa/hygro transfectants; difference = 88%, 95% CI = 65% to 100%; P =.01) or untransfected SiHa cells. All seven mice (100%, 95% CI = 59% to 100%) injected with untransfected SiHa cells or SiHa/hygro transfectants displayed tumors of at least 50 mm(3) by 2-6 weeks after injection compared with none of eight mice (0%, 95% CI = 0% to 37%) injected with the SiHa/TSLC1 transfectants (difference = 100%, 95% CI = 68% to 100%; P<.001). We detected TSLC1 promoter hypermethylation in seven (35%, 95% CI = 15% to 59%) of 20 high-grade CIN lesions (i.e., CIN II and III) and in 30 (58%, 95% CI = 43% to 71%) of 52 cervical squamous cell carcinomas compared with none (0%, 95% CI = 0% to 34%) of nine normal cervical epithelial biopsy samples and none (0%, 95% CI = 0% to 22%) of 12 CIN I lesions (P<.001 for cervical squamous cell cancer versus normal epithelial biopsy samples plus CIN I lesions). CONCLUSIONS: TSLC1 gene silencing via promoter hypermethylation is a frequent event in the progression from high-risk HPV-containing, high-grade CIN lesions to invasive cervical cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Frommer, M., McDonald, L. E., Millar, D. S., Collis, C. M., Watt, F., Grigg, G. W., Molloy, P. L., & Paul, C. L. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.5.1827 · Cited by 3,238
The 2001 Bethesda System<SUBTITLE>Terminology for Reporting Results of Cervical Cytology</SUBTITLE>
Solomon, D. (2002) · JAMA · doi:10.1001/jama.287.16.2114 · Cited by 3,104
Cited by
Narisawa‐Saito, M., & Kiyono, T. (2007) · Cancer Science · doi:10.1111/j.1349-7006.2007.00546.x · Cited by 528
HPV‐mediated cervical carcinogenesis: concepts and clinical implications
Snijders, P. J., Steenbergen, R. D., Heideman, D. A., & Meijer, C. J. (2006) · The Journal of Pathology · doi:10.1002/path.1866 · Cited by 455
Self-citationClinical implications of (epi)genetic changes in HPV-induced cervical precancerous lesions
Steenbergen, R. D. M., Snijders, P. J. F., Heideman, D. A. M., & Meijer, C. J. L. M. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3728 · Cited by 386
Self-citationWentzensen, N., Sherman, M. E., Schiffman, M., & Wang, S. S. (2009) · Gynecologic Oncology · doi:10.1016/j.ygyno.2008.10.012 · Cited by 263
Methylation-mediated silencing and tumour suppressive function of hsa-miR-124 in cervical cancer
Wilting, S. M., van Boerdonk, R. A., Henken, F. E., Meijer, C. J., Diosdado, B., Meijer, G. A., le Sage, C., Agami, R., Snijders, P. J., & Steenbergen, R. D. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-167 · Cited by 258
Self-citation
Metadata
- Authors
- Steenbergen, R. D. M., Kramer, D., Braakhuis, B. J. M., Stern, P. L., Verheijen, R. H. M., Meijer, C. J. L. M., & Snijders, P. J. F.
- Venue
- JNCI Journal of the National Cancer Institute
- Publisher
- Oxford University Press (OUP)
- Published
- 2004-02-17
- Volume
- 96
- Issue
- 4
- Pages
- 294-305
- ISSN
- 0027-8874 (ISSN-L)
- 1460-2105
- OpenAlex
- W2167533065
- Cited by
- 203
- References
- 2
- FWCI
- 8.78
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: TSLC1 Gene Silencing in Cervical Cancer Cell Lines and Cervical Neoplasia. https://app.cochat.ai/papers/10.1093/jnci/djh031
- The paper
- Steenbergen, R. D. M., Kramer, D., Braakhuis, B. J. M., Stern, P. L., Verheijen, R. H. M., Meijer, C. J. L. M., & Snijders, P. J. F. (2004). TSLC1 Gene Silencing in Cervical Cancer Cell Lines and Cervical Neoplasia. JNCI Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djh031
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.